A more connected path to cancer care.
Bringing the journey together. From initial testing in the US to planned immunotherapy treatment and recovery in India.
Coordination, not clinical decisions.
IMT is being built to hold the practical threads of a US-to-India treatment journey so patients and families can focus on care itself.
Cell-based immunotherapies involve many hand-offs: testing in one place, manufacturing in another, treatment and recovery somewhere else, and follow-up at home. Each hand-off is a place where information, timing, and support can fall through the cracks.
Indian Medical Travel's intended role is to coordinate that sequence. We are designing the logistics, communication, and planning support that connect US-based evaluation with planned treatment in India and a safe return home.
Coordination across borders
Sequencing appointments, travel, accommodation, records, and communication between the teams involved at each stage.
Clear, honest information
Plain-language explanations of what each stage involves, what is known, and what is still uncertain, so decisions are made with your own clinicians.
Support for the whole journey
Planning for caregivers, recovery time, readiness to travel, and follow-up care once you are home.
IMT does not diagnose, recommend, or provide treatment. Every clinical step, from eligibility to therapy choice to follow-up, depends on the specific treatment, the treating clinical team, and an individual assessment of each patient. Your oncology team remains central to every decision.
The planned care journey
A four-stage model we are developing. The exact steps will depend on the therapy, the clinical teams involved, and your individual situation.
Understand your options
Discuss whether a cell-based immunotherapy could be relevant for you in consultation with your current oncology team.
- Review diagnosis and prior treatment
- Ask about evidence, risks, and alternatives
- Decide whether to explore further
Initial evaluation and testing
Clinical evaluation and testing, including sequencing where appropriate, performed in the US before any travel is planned.
- Eligibility assessment by clinicians
- Laboratory and sequencing tests as indicated
- Records organised for the next stage
Therapy preparation and treatment
Therapy synthesis or manufacturing in India, followed by patient travel to India for treatment with the treating clinical team.
- Manufacturing timelines set by the therapy
- Travel and accommodation coordinated
- Treatment and close monitoring in hospital
Recovery and follow-up
Post-treatment care in India until clinicians confirm readiness to travel, then coordinated follow-up with your care team at home.
- Recovery period and fitness-to-fly assessment
- Complete records in English to take home
- Follow-up plan agreed before departure
Helping the immune system recognise cancer
A plain-language introduction, drawn from the National Cancer Institute. It is general education, not advice about your own care.
What immunotherapy is
Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. Immune cells normally find and destroy abnormal cells, but cancer can hide from them or switch them off. Immunotherapy strengthens the body's response against the cancer.
Cell-based therapies
Some immunotherapies, such as CAR T-cell therapy, use a patient's own immune cells. T cells are collected from the blood, modified in a laboratory so they can recognise a target on cancer cells, grown to large numbers, and returned to the patient as an infusion.
Who it is for
These therapies are suitable only for particular clinical situations. Currently approved CAR T-cell therapies are used for certain blood cancers, including some leukemias, lymphomas, and multiple myeloma, often after other treatments have stopped working.
Serious side effects are possible
The National Cancer Institute describes several serious effects of CAR T-cell therapy, which is why it is given by specialist teams in hospital.
- Cytokine release syndrome, with high fevers and drops in blood pressure
- Neurologic effects such as confusion or impaired speech
- Infections and loss of antibody-producing B cells
Clinical assessment is required
Whether any immunotherapy is appropriate depends on the cancer type, prior treatment, overall health, and the judgement of the treating clinicians. Not every therapy that exists is right, available, or approved for every patient.
IMT does not offer a particular approved therapy at this time and makes no claims about treatment outcomes.
Sources: National Cancer Institute, Immunotherapy to Treat Cancer and CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers.
Good questions before any decision
Whatever path you consider, these questions are worth asking any provider, in any country. Many are drawn from the CDC's guidance on receiving medical care abroad.
About the treatment
- What is the evidence that this treatment works for my cancer and stage?
- Am I eligible, and how was that determined?
- What are the serious risks, and how are they managed?
- What are the alternatives, including standard care or doing nothing further?
- Is this treatment approved by a regulator, part of a registered clinical trial, or neither?
About the provider and the trip
- What are the credentials of the clinicians, and is the facility accredited?
- How will my care team here and the team abroad communicate?
- Am I fit to travel, and how long after treatment before I can fly?
- What support will my caregiver need, and where will we stay?
- What exactly does the quoted cost include, and what happens if complications arise?
Planning ahead
- Gather complete medical records, lab results, and an allergy and medication list.
- Know where you would receive emergency care, both abroad and at home.
- Check whether your insurance covers care abroad, and consider travel health insurance that includes medical evacuation.
- Ask for a complete set of records in English before leaving any facility.
- Agree a follow-up plan with your home clinicians before you travel.
Honest answers, where we have them
We would rather say "not yet confirmed" than guess. These answers will be updated as the program develops.
Is IMT accepting patients?
No. Indian Medical Travel is in development and patient enrollment is not open. You are welcome to contact us with general questions or to ask to be notified when we launch.
Which treatments will be available?
We are exploring cell-based immunotherapies similar to CAR T-cell therapy. No specific therapy, cancer indication, laboratory, hospital, or clinical team has been confirmed. We will publish details only once they are established.
What happens in the US versus India?
In the planned model, initial evaluation and testing, including sequencing where appropriate, take place in the United States. Therapy preparation or manufacturing, treatment, and the initial recovery period are planned to take place in India. Follow-up is then coordinated with your care team at home.
This sequence is a planned design and may change as the program develops.
How is treatment suitability determined?
By clinicians, not by IMT. Suitability depends on the specific therapy, the cancer type and stage, prior treatment, overall health, and an individual assessment by the treating team. We encourage every patient to discuss options with their current oncology team first.
What will it cost?
Pricing has not been set, and we do not publish estimates or savings comparisons before they are real. When the program launches, we intend to provide clear, itemised information about what is and is not included, including travel, accommodation, and follow-up.
How long would a patient stay in India?
We do not yet have a confirmed timeline. The length of stay would depend on the therapy, the treating team's monitoring requirements, individual recovery, and when clinicians consider a patient fit to travel. Public health guidance generally advises against flying soon after major treatment, so a recovery period in India should be expected.
Are the treatments approved in the US or India?
We cannot answer this yet because no specific therapy has been confirmed. Several CAR T-cell therapies are approved by the US FDA for certain blood cancers. The regulatory status of any therapy offered through IMT, in either country, will be stated clearly before enrollment opens. Ask any provider whether a treatment is regulator-approved, part of a registered clinical trial, or neither.
Should patients send medical records now?
No. Please do not email medical records, test results, or other sensitive health information. We are not accepting patients, and ordinary email is not a secure channel for health data. General questions are welcome.
We would like to hear from you
General inquiries, questions about our approach, and requests to be told when we launch are all welcome. We reply by email, personally.
Do not email medical records, scans, test results, or other sensitive health details. Email is not a secure channel, and we are not yet accepting patients.
There is no automated mailing list. If you ask, we will note your request and write to you when there is news.
Indian Medical Travel is a new company based in the United States, preparing a coordinated US-to-India care pathway.